Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort

Rodríguez, Carmen; Jacobs, Eric J.; Deka, Anusila; Patel, Alpa V.; Bain, Elizabeth B.; Thun, Michael J.; Calle, Eugenia E.

doi:10.1007/s10552-008-9280-0

Cited by 46 publications

(46 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,6,13,15,18,[22][23][24]27,31,33 When the analyses were restricted to studies that investigated the effect of only ACE inhibitors on cancer risk, the 12 cohort and nested case-control studies showed a nonsignificant protective effect (RR 0.93, 95% CI 0.86-1.01), 4,12,15,16,19,21,23,29−33 and the 8 studies with longterm follow-up showed a significant protective effect (RR 0.89, 95% CI 0.80-0.98). 4,13,15,18,22,23,31,33 No significant change was observed when we excluded two studies with crude estimates. 11,28 In the subgroup analyses by study design (Figure 2) analysis of the conventional case-control studies (RR 1.14, 95% CI 1.00-1.31).…”

Section: Effect Of Medication Use On Risk Of Cancermentioning

confidence: 99%

Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies

Yoon¹,

Yang²,

Jeon³

et al. 2011

CMAJ

View full text Add to dashboard Cite

R ecent meta-analyses have shown a possible increased risk of cancer associated with angiotensin-receptor blockers used alone or combined with angiotensin-convertingenzyme (ACE) inhibitors.1,2 Despite the strong internal validity of randomized controlled trials (RCTs) used in prior meta-analyses, it is difficult to interpret these results because of the short duration of follow-up for cancer detection.3 A previous retrospective cohort study with a mean follow-up of 6.6 years showed that the use of ACE inhibitors was associated with a significantly de creased risk of overall cancer, and cancer of the lung, breast and female reproductive organs and smoking-related cancers. 4 Despite the inconsistent results reported by previous observational studies regarding this issue, 4−35 we conducted a meta-analysis of cohort and casecontrol studies to assess the association between use of these medications and the risk of cancer. Methods Literature searchWe searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library up to January 2011 using common keywords related to ACE inhibitors, angiotensin-receptor blockers and cancer. The search terms were as follows: "angiotensin-converting enzyme inhibitor" or "angiotensin receptor blocker" or trade names of the medications AND "cancer" or "carcinoma" or "neoplasm" or "malignancy" or names of specific types of cancer. (For details about the search strategy, see Appendix 1, at www.cmaj.ca /lookup /suppl/doi:10.1503 /cmaj .101497 /-/DC1.) We also reviewed the bibliographies of relevant articles to identify additional publications. Studies were restricted to those involving humans. We performed a meta-analysis of observational studies to assess the association.

show abstract

Section: Effect Of Medication Use On Risk Of Cancermentioning

confidence: 99%

Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies

Yoon¹,

Yang²,

Jeon³

et al. 2011

CMAJ

View full text Add to dashboard Cite

show abstract

“…Less clear is the effect of calcium channel blockers in cancer, particularly prostate cancer. Thus, whereas some investigators report that the use of calcium channel blockers is inversely associated with prostate cancer (Debes et al, 2004), others have failed to find such a relationship (Rodriguez et al, 2009). Thus, it is of interest to investigate the potential effectiveness of these drugs in prostate cancer therapy, especially because both cardiovascular problems and prostate cancer are common in elderly men (Yoshinaga et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

Diltiazem Enhances the Apoptotic Effects of Proteasome Inhibitors to Induce Prostate Cancer Cell Death

Kaddour‐Djebbar¹,

Choudhary²,

Lakshmikanthan³

et al. 2012

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Diltiazem is a calcium channel blocker used to treat cardiovascular ailments. In addition, reports suggest that diltiazem induces cell death, which could make it a drug of choice for the treatment of cancer associated with hypertension. The goal of this research was to determine whether diltiazem is capable of inducing apoptosis in prostate cancer cells, either alone or in combination with the proteasome inhibitors, lactacystin and bortezomib (Velcade). Bortezomib is approved for the treatment of multiple myeloma; unfortunately, it has side effects that limit its utility. Presumably these side effects could be decreased by reducing its dose in combination with another drug. We have previously shown that lactacystin induces apoptosis in LNCaP cells; here, we show that this effect was enhanced by diltiazem. Furthermore, in proteasome inhibitor-resistant DU145 cells, diltiazem alone did not induce apoptosis but decreased cytosolic calcium levels and induced mitochondrial fission; likewise, lactacystin did not induce apoptosis but up-regulated the proapoptotic protein Bik. However, increasing concentrations of diltiazem in combination with lactacystin or bortezomib induced apoptosis in a dose-dependent and synergistic manner. The combination of diltiazem and lactacystin also up-regulated the levels of Bik and released Bak from Bcl-xL, indicating the involvement of the Bcl2 family pathway in this apoptosis. In addition, the drug combination up-regulated GRP78, suggesting also the involvement of endoplasmic reticulum stress in the apoptotic response. Thus, our results demonstrate a potential therapeutic advantage of combining a frequently used calcium channel blocker with proteasome inhibitors in the treatment of prostate cancer.

show abstract

“…Several studies have been conducted on the subject, with conflicting results. Positive results are reported for individual drugs, classes of drugs (such as calcium-channel blockers and beta-blockers), and blood pressure medication as a whole, but there are also studies that fail to report such findings [2,[4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case–control study

Kemppainen

Tammela

Auvinen

et al. 2011

Cancer Causes Control

View full text Add to dashboard Cite

Some studies have suggested that use of antihypertensive drugs could decrease prostate cancer risk. We evaluated this association at the population level. All prostate cancer cases in Finland during 1995-2002 and matched controls (24,657 case-control pairs) were identified from the Finnish Cancer Registry and the Population Register Center, respectively. Detailed information on antihypertensive drug purchases was obtained from a national prescription database. Data were analyzed using multivariable-adjusted conditional logistic regression model. Ever use of antihypertensive drugs was associated with marginally elevated overall prostate cancer risk (OR 1.16; 95% CI, 1.12-1.21). Risk of advanced prostate cancer did not differ from the nonusers (OR 1.08, 95% CI 0.98-1.18). The risk increase was observed constantly in all classes of antihypertensive drugs. Our large population-based study generally does not support decreased risk of prostate cancer among antihypertensive drug users. Conversely, an increased overall prostate cancer risk was observed. The association being similar for all drug groups suggests that it is probably caused by a systematic difference between medication users and nonusers, such as differing PSA testing activity.

show abstract

Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort

Abstract: These results do not support the hypothesis that anti-hypertensive medication is strongly associated with risk of prostate cancer. Confounding by concurrent illness may explain inverse associations seen in other studies.

Cited by 46 publications

References 25 publications

Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies

Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies

Diltiazem Enhances the Apoptotic Effects of Proteasome Inhibitors to Induce Prostate Cancer Cell Death

The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case–control study

Contact Info

Product

Resources

About